右美托咪定对急诊创伤手术患者创伤后应激障碍的影响:一项随机临床试验
这项双盲随机临床试验于2022年1月22日至10月20日在中国江苏省4家医院开展,入选急诊创伤手术患者,术后随访1个月。干预组从麻醉开始至手术结束以0.1 μg/kg/h维持剂量泵注右美托咪定,术后第1至3天每晚9点至早7点以相同速率给药;对照组给予生理盐水。主要终点为术后1个月PTSD发生率(CAPS-5评估),右美托咪定组显著低于对照组(14.1% vs 24.0%,P=0.03),CAPS-5评分亦显著更低(17.3[5.3] vs 18.9[6.6],均数差1.65,95%CI 0.31-2.99,P=0.02),校正混杂因素后adjusted OR 0.51(95%CI 0.27-0.94,P=0.03)。作者结论认为该结果支持在急诊创伤手术中使用右美托咪定。
要点
- 急诊创伤手术患者从麻醉开始至手术结束及术后第1至3天晚9点至早7点泵注右美托咪定0.1 μg/kg/h,术后1个月PTSD发生率为14.1% vs 对照组24.0%(P=0.03)。
- 右美托咪定组CAPS-5评分为17.3(5.3),对照组为18.9(6.6),均数差1.65(95%CI 0.31-2.99,P=0.02)。
- 校正潜在混杂因素后,右美托咪定组术后1个月发生PTSD的风险更低(adjusted OR 0.51,95%CI 0.27-0.94,P=0.03)。
- 共310例纳入改良意向性分析(生理盐水组154例,右美托咪定组156例),平均(SD)年龄40.2(10.3)岁,男性179例(57.7%)。
- 作者结论认为,术中及术后给予右美托咪定降低了创伤患者的PTSD发生率,该试验结果支持在急诊创伤手术中使用右美托咪定。
适用人群与场景
- 在中国江苏省4家医院接受急诊手术的创伤患者,术后随访1个月。
- 共筛查477例,310例纳入改良意向性分析(生理盐水组154例,右美托咪定组156例)。
处置流程与药物剂量
- 右美托咪定从麻醉开始至手术结束以维持剂量0.1 μg/kg/h给药,术后第1至3天每晚9点至早7点以相同速率给药(0.1 μg/kg/h)。
- 对照组给予安慰剂(生理盐水)。
研究设计与关键结果
- 研究类型:双盲随机临床试验,在江苏省4家医院开展,2022年1月22日至10月20日纳入患者,术后随访1个月。
- 主要终点:术后1个月PTSD发生率(CAPS-5评估),右美托咪定组14.1% vs 对照组24.0%,P=0.03。
- CAPS-5评分:右美托咪定组17.3(5.3) vs 对照组18.9(6.6),均数差1.65(95%CI 0.31-2.99),P=0.02。
- 校正潜在混杂因素后,右美托咪定组术后1个月发生PTSD的可能性更低(adjusted OR 0.51,95%CI 0.27-0.94,P=0.03)。
- 次要终点包括术后48小时内及术后1个月疼痛评分、术后谵妄、恶心、瘙痒发生率、主观睡眠质量、焦虑及不良事件发生情况。
证据类型、等级与局限
- 证据类型:随机临床试验(双盲)。
- 试验注册:中国临床试验注册中心 ChiCTR2200056162。
对床旁实践的改变
- 作者结论认为,术中及术后给予右美托咪定降低了创伤患者的PTSD发生率,该试验结果支持在急诊创伤手术中使用右美托咪定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Posttraumatic stress disorder (PTSD) is common in people who have experienced trauma, especially those hospitalized for surgery. Dexmedetomidine may reduce or reverse the early consolidation and formation of conditioned fear memory and prevent the occurrence of postoperative PTSD.
OBJECTIVE: To evaluate the effects of intraoperative and postoperative low-dose intravenous pumping dexmedetomidine on PTSD among patients with trauma undergoing emergency surgery.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial was conducted from January 22 to October 20, 2022, with follow-up 1 month postoperatively, in patients with trauma undergoing emergency surgery at 4 hospital centers in Jiangsu Province, China. A total of 477 participants were screened. The observers were blinded to patient groupings, particularly for subjective measurements.
INTERVENTIONS: Dexmedetomidine or placebo (normal saline) was administered at a maintenance dose of 0.1 μg/kg hourly from the start of anesthesia until the end of surgery and at the same rate after surgery from 9 pm to 7 am on days 1 to 3.
MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in the incidence of PTSD 1 month after surgery in the 2 groups. This outcome was assessed with the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (CAPS-5). The secondary outcomes were the pain score within 48 hours and 1 month postoperatively; incidence of postoperative delirium, nausea, and pruritus; subjective sleep quality; anxiety; and occurrence of adverse events.
RESULTS: A total of 310 patients (154 in the normal saline group and 156 in the dexmedetomidine group) were included in the modified intention-to-treat analysis (mean [SD] age, 40.2 [10.3] years; 179 men [57.7%]). The incidence of PTSD was significantly lower in the dexmedetomidine group than in the control group 1 month postoperatively (14.1% vs 24.0%; P = .03). The participants in the dexmedetomidine group had a significantly lower CAPS-5 score than those in the control group (17.3 [5.3] vs 18.9 [6.6]; mean difference, 1.65; 95% CI, 0.31-2.99; P = .02). After adjusting for potential confounders, the patients in the dexmedetomidine group were less likely to develop PTSD than those in the control group 1 month postoperatively (adjusted odds ratio, 0.51; 95% CI, 0.27-0.94; P = .03).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the administration of intraoperative and postoperative dexmedetomidine reduced the incidence of PTSD among patients with trauma. The findings of this trial support the use of dexmedetomidine in emergency trauma surgery.
TRIAL REGISTRATION: Chinese Clinical Trial Register Identifier: ChiCTR2200056162.
参考来源
- Yu Y, Li Y, Han D, et al. Effect of Dexmedetomidine on Posttraumatic Stress Disorder in Patients Undergoing Emergency Trauma Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37326991. doi:10.1001/jamanetworkopen.2023.18611
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。